Assenagon Asset Management S.A. 13F: Adds $240M to VRTX Stake

Assenagon Asset Management S.A. has boosted its stake in Vertex Pharmaceuticals Incorporated (VRTX) in a recent filing on October 15, 2026. The firm added 459,747 shares, increasing its total position to 1,219,311 shares worth approximately $637.5 million. This reflects a 60.5% increase in their holdings since the previous quarter, when they held 759,564 shares.

What Changed in Assenagon Asset Management's Vertex Position

Assenagon's latest adjustment shows a significant commitment to Vertex Pharmaceuticals, growing its shares by 459,747. After this addition, the fund now owns 1,219,311 shares in the biotech company, indicating a strong belief in Vertex's future potential.

Other Institutional Activity in Vertex Pharmaceuticals

In the latest quarter, several other institutional investors have also made movements regarding Vertex Pharmaceuticals. Capital World Investors grew its holdings by 745,853 shares, ending with 26,115,014 shares worth about $13.05 billion. Blackrock Inc. added 139,028 shares for a total of 24,109,373 shares valued at approximately $12.05 billion. Vanguard Capital Management LLC saw a modest increase of 67,703 shares, bringing its total to 16,580,713 shares worth around $8.29 billion.

Vertex Pharmaceuticals Incorporated Stock Down 1.8%

Vertex Pharmaceuticals trades recently around $499.42 as of October 16, 2026. This price is below its 50-day moving average of about $522.23 and 10.9% under its 52-week high of $560.25, suggesting a potential for upward movement as conditions improve.

Recent Earnings

In its last reported earnings, Vertex Pharmaceuticals generated a trailing twelve-month revenue of approximately $12.59 billion with an EPS of $17.17. The company has shown a year-over-year revenue growth of 12.5%. Its next earnings announcement is scheduled for November 2, 2026, which will provide further insights into its financial health.

Insider Buying and Selling at Vertex Pharmaceuticals Incorporated

Recent insider trades at Vertex include several sales by company officers. On June 26, 2026, Officer Carmen Bozic sold 596 shares at an average price of $482.50, totaling about $287,570. Joy Liu, another officer, sold 828 shares on July 1 at $502.71, worth around $416,244. Similarly, Ourania Tatsis sold 1,500 shares on July 2 at $524.99 for about $787,485, and Duncan J. Mckechnie sold 1,541 shares the same day at $519, totaling approximately $799,779.

Analysts Set New Price Targets

On August 4, 2026, TD Cowen maintained a 'Buy' rating for Vertex, raising its price target from $525 to $550. Truist Securities followed suit on August 5, also maintaining a 'Buy' rating while increasing its target from $560 to $565. Barclays kept an 'Overweight' rating with a target of $617. The consensus among analysts remains positive, with a mean price target of $571.46 from 28 opinions, suggesting strong confidence in Vertex's prospects.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology company that focuses on developing transformative medicines. They target serious diseases, primarily in specialty markets such as cystic fibrosis and sickle cell disease. The recent increase in Assenagon's stake reflects ongoing confidence in Vertex's innovative pipeline and growth potential.

Bottom Line

Investors will want to watch Vertex Pharmaceuticals closely as it approaches its next earnings date on November 2, 2026. The recent position changes among institutional investors, including Assenagon's significant boost, highlight the ongoing interest in the company's future performance. Keep in mind that this filing reflects holdings as of the end of the reporting quarter and may not represent the current position of the fund.